obeticholic acid

A farnesoid X receptor agonist and anticholestatic agent that is used in the treatment of chronic liver diseases; structure in first source.

Also Known As:

6-ECDCA; 6-ethyl chenodeoxycholic acid; 6-ethyl-3,7-dihydroxycholan-24-oic acid; 6-ethylchenodeoxycholic acid; 6ECDCA; 6alpha-ethyl-3alpha,7alpha-dihydroxy-5beta-cholan-24-oic acid; 6alpha-ethyl-chenodeoxycholic acid; DSP-1747; DSP1747; INT 747; INT-747; INT747; Ocaliva; cholan-24-oic acid, 6-ethyl-3,7-dihydroxy-, (3alpha,5beta,6alpha,7alpha)-

Networked: 319 relevant articles (49 outcomes, 69 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Bile Acids and Salts: 11432
      - Cholic Acids: 14
        Deoxycholic Acid: 963
        Chenodeoxycholic Acid: 877
        obeticholic acid: 319
    - Cholanes
      - Cholic Acids: 14
        Deoxycholic Acid: 963
        Chenodeoxycholic Acid: 877
        obeticholic acid: 319

Experts

1.	Adorini, Luciano: 18 articles (04/2022 - 11/2010)
2.	Kowdley, Kris V: 16 articles (09/2021 - 03/2015)
3.	Shapiro, David: 13 articles (01/2021 - 09/2013)
4.	Loomba, Rohit: 12 articles (01/2022 - 03/2015)
5.	Sanyal, Arun J: 12 articles (01/2022 - 09/2013)
6.	MacConell, Leigh: 10 articles (02/2021 - 08/2016)
7.	Nevens, Frederik: 9 articles (01/2021 - 06/2014)
8.	Fiorucci, Stefano: 9 articles (01/2020 - 08/2002)
9.	Parés, Albert: 8 articles (11/2021 - 01/2015)
10.	Hirschfield, Gideon M: 8 articles (02/2021 - 04/2015)

Related Diseases

1.	Fibrosis (Cirrhosis) 01/01/2022 - "Patient-reported outcomes (PROs) evaluating HRQoL were assessed in the RandomizEd Global Phase 3 Study to Evaluate the Impact on NASH with FibRosis of Obeticholic Acid TreatmEnt (REGENERATE) study, which showed that obeticholic acid (OCA) significantly improved fibrosis in patients with NASH. " 01/01/2021 - "In the 18-month interim analysis of an ongoing randomized, placebo-controlled phase 3 trial (REGENERATE), early results demonstrated that obeticholic acid (OCA) 25 mg significantly improved fibrosis with no worsening of NASH among patients with NASH and fibrosis compared with placebo (PBO). " 12/01/2019 - "A phase 3 trial evaluating obeticholic acid have shown a 72 weeks duration treatment improved significantly fibrosis." 07/01/2022 - "Obeticholic acid had a significant improvement on fibrosis. " 12/14/2019 - "Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. "
2.	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 01/01/2022 - "Obeticholic acid (OCA), a steroidal BA-like FXR agonist, has been shown to improve liver function in patients with primary biliary cholangitis and is approved as second-line treatment for patients with an inadequate response or intolerance to UDCA. " 02/01/2021 - "Long-Term Efficacy and Safety of Obeticholic Acid in Primary Biliary Cholangitis: Responder Analysis of More Than 5 Years of Treatment in the POISE Trial." 02/01/2021 - "Long-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial." 01/01/2019 - "The aim of this study was to evaluate the long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis using 3-year interim data from the 5-year open-label extension of the pivotal phase 3 POISE trial. " 01/01/2019 - "Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study."
3.	Inflammation (Inflammations) 10/01/2016 - "The Role of Obeticholic Acid in Gut Bacterial Translocation and Inflammation." 05/01/2016 - "Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats." 02/01/2015 - "We studied potential intestinal FXR dysfunction in a rat model of cholestatic liver injury and evaluated effects of obeticholic acid (INT-747), an FXR agonist, on gut permeability, inflammation, and BTL. " 11/15/2019 - "Generally, treatment with obeticholic acid improved hepatic histology, including inflammation and fibrosis, the latter being the main histological predictor of advanced disease. " 11/01/2018 - "The FXR agonist obeticholic acid (OCA) is licensed for the treatment of primary biliary cholangitis and has shown promising results in NASH patients, whereas TGR5 agonists target inflammation and metabolism. "
4.	Non-alcoholic Fatty Liver Disease 01/01/2021 - "Late-stage clinical trials investigating the use of obeticholic acid in the treatment of nonalcoholic steatohepatitis are underway. " 09/01/2020 - "For some of them, e.g., obeticholic acid, advanced stage clinical trials indicate antifibrotic efficacy in NAFLD and NASH. " 01/01/2019 - "Purpose: The objective of this study was to identify the role of farnesoid X receptor agonist obeticholic acid via targeting gut microbiota in NAFLD. " 01/01/2023 - "The response rate to obeticholic acid (OCA), a potential therapeutic agent for non-alcoholic fatty liver disease, is limited. " 01/01/2023 - "Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice."
5.	Liver Diseases (Liver Disease) 05/01/2011 - "This recent finding has now opened the door for future therapeutic trials for use of FXR agonists such as obeticholic acid for the treatment of chronic cholestatic liver diseases. " 01/01/2023 - "Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals." 05/01/2021 - "Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis." 01/01/2020 - "Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid." 11/01/2019 - "The nuclear farnesoid X receptor (FXR) agonist obeticholic acid (OCA) has been developed for the treatment of liver diseases. "

Related Drugs and Biologics

1.	Ursodeoxycholic Acid (Urso)
2.	Bile Acids and Salts (Bile Acids)
3.	Ligands
4.	Fibric Acids (Fibrates)
5.	lanifibranor
6.	Glucose (Dextrose)
7.	Bezafibrate
8.	resmetirom
9.	aldafermin
10.	2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acid

Related Therapies and Procedures

1.	Therapeutics
2.	Ligation
3.	Drug Tapering
4.	Drug Therapy (Chemotherapy)
5.	Liver Transplantation